Healthcare & Life Sciences Limited’s (GOVX)stock price has been under tremendous selling pressure over the past six months, due in large part to the unwinding of previous financings. That unwinding is still taking place. As of September 30, 2019, the outstanding common share count totaled 95.6 million, up from 0.8 million at the end of June 30, 2019 and 6.0 million at August 31, 2019. The increase is due almost entirely to the conversion of preferred stock by the company’s primary investors. Current stockholders are feeling the pain of this massive dilution. Yet, lost in the downward spiral is recent positive news by the company relating to its efforts in immuno-oncology. Company officials believe that at some point, the primary investors will cease the conversions and sales. Together with Healthcare & Life Sciences Limited Chairman, President, and CEO, David Dodd we are providing an update in a question-and-answer format on the unwinding of the financings and the company's plans to advance the business in 2020.  

For the full Q&A Click HERE